Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cinobufagin in medicine for treating acute myelogenous leukemia

A technology for cinobufin-based and myeloid leukemia, which is applied in the field of medicine

Inactive Publication Date: 2021-08-10
SHENZHEN PEOPLES HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, with the deepening of research, the problem of primary and secondary drug resistance of these new drugs has gradually emerged, which has brought new challenges to the treatment of AML
In addition, although AML treatment options are improving day by day, for elderly patients who cannot tolerate high-intensity chemotherapy and patients with refractory AML, more new drugs with low toxicity and high potency are still needed for clinical selection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cinobufagin in medicine for treating acute myelogenous leukemia
  • Application of cinobufagin in medicine for treating acute myelogenous leukemia
  • Application of cinobufagin in medicine for treating acute myelogenous leukemia

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0026] AML cell lines THP-1 and HL60 and other leukemia cell lines Jurkat, Raji, U937, HEL92.1.7 or Molt4 were cultured, and 3×10 4 Cells were seeded in a 96-well plate at a final concentration of 100.00 μM, 50.00 μM, 25.00 μM, 12.50 μM, 6.20 μM, 3.10 μM, 1.50 μM, 0.80 μM, 0.40 μM, 0.20 μM, 0.10 μM, 0.05 μM and 0 μM The cinobufaction base was treated for 18 hours, and then the CellTiter-Lumi TM The requirements for the use of the luminescent cell viability detection kit are to detect cell viability.

[0027] After detection, the 0 μM group was regarded as the control group, and the cell viability was counted as 100%, and the relative cell viability of other groups was calculated. Then use GraphPad software, take the logarithmic value of the cinobufaction base concentration as the abscissa, and take the relative cell viability as the ordinate, to obtain the relationship between the concentration of the cinobufin base and the cell viability (such as figure 1 ).

[0028] The i...

experiment example 2

[0031] 2105 cells of AML cell lines THP-1 and HL60 were inoculated in 48-well plates, treated with 1 μM cinobufaction base for 18 hours, the culture supernatant was collected by centrifugation, and the contents of IL1β and IL18 in the supernatant were analyzed by ELISA , the data results are as image 3 shown. It was confirmed that when cinobufaction base induces the death of THP-1 and HL60 cells, it will secrete inflammatory factors IL1β and IL18, which can effectively regulate the tumor immune microenvironment and activate the anti-tumor immune response mediated by T cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of cinobufagin in a medicine for treating acute myelogenous leukemia. The cinobufagin is used for inducing swelling death of cells HL60 and THP-1 of an AML cell line, and meanwhile, massive secretion of inflammatory factors IL1beta and IL18 is caused. The invention indicates that the cinobufagin can induce inflammatory death in a classic pyroptosis form of the AML cells in a targeted mode, and also shows that the cinobufagin has a potential treatment effect on the AML.

Description

technical field [0001] The invention is applied in the technical field of medicines, in particular the application of cinobufaction toxin base in medicines for treating acute myeloid leukemia. Background technique [0002] Acute myeloid leukemia (AML) is an aggressive hematological malignancy and the most common acute leukemia in adults, with a combined five-year survival rate of only about 30%. AML can occur in all age groups, but mainly occurs in people over the age of 60. For young AML patients, the five-year survival rate is about 40%, but with increasing age, especially for patients over 60 years old, the five-year survival rate is only 5% to 15%. From 1990 to 2017, the incidence of AML in the world gradually increased. With the deepening of the aging society, it has become a dangerous disease that seriously threatens the life and health of our people. At present, except that all-trans retinoic acid has played a revolutionary role in the treatment of M3 type AML by in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/585A61P35/02A61P9/04
CPCA61K31/585A61P35/02A61P9/04
Inventor 张其清杨威
Owner SHENZHEN PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com